Leukemia, Myeloid, Acute: all 3,035 studies

Page 10 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.

• Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 MutationActive, not recruitingNCT03173248Phase 3Results posted
• Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)TerminatedNCT03154827Phase 1/2Results posted
• CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CRTerminatedNCT03152526Not applicableResults posted
• An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid LeukemiaTerminatedNCT03151408Phase 3Results posted
• Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)TerminatedNCT03150004Phase 2Results posted
• Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating AgentTerminatedNCT03146871Phase 2Results posted
• Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese AdultsTerminatedNCT03135028Phase 1Results posted
• DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)TerminatedNCT03110354Phase 1Results posted
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
• Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT03092674Phase 2/3Results posted
• Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid NeoplasmsCompletedNCT03072043Phase 1/2Results posted
• Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT03071276Phase 2Results posted
• A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyCompletedNCT03069352Phase 3Results posted
• Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell TransplantCompletedNCT03068819Phase 1/2Results posted
• Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeTerminatedNCT03067571Phase 2Results posted
• Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT03063203Phase 2Results posted
• Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and NeutropeniaCompletedNCT03019939Phase 2Results posted
• Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid NeoplasmCompletedNCT03012672Phase 2Results posted
• MEN1703 (SEL24) in Participants With Acute Myeloid LeukemiaCompletedNCT03008187Phase 1/2Results posted
• Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood CancerTerminatedNCT02999854Phase 3Results posted
• A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)CompletedNCT02997202Phase 3Results posted
• Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT02996474Phase 1/2Results posted
• A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction TherapyActive, not recruitingNCT02993523Phase 3Results posted
• Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesTerminatedNCT02991898Phase 2Results posted
• Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCTCompletedNCT02989844Phase 2Results posted
• Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) MutationCompletedNCT02984995Phase 2Results posted
• Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell TransplantationCompletedNCT02981914Early Phase 1Results posted
• Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02971397Phase 1Results posted
• A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid LeukemiaTerminatedNCT02954653Phase 1Results posted
• Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT02953561Phase 1/2Results posted
• Leukemia Stem Cell Detection in Acute Myeloid LeukemiaTerminatedNCT02927938Phase 3Results posted
• A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete RemissionCompletedNCT02927262Phase 2Results posted
• Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDSCompletedNCT02921061Phase 1/2Results posted
• Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid LeukemiaCompletedNCT02920008Phase 3Results posted
• Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid LeukemiaActive, not recruitingNCT02890329Phase 1Results posted
• Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02882321Phase 1Results posted
• Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02873338Phase 2Results posted
• A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic SyndromesTerminatedNCT02848001Phase 1Results posted
• Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older PatientsCompletedNCT02845297Phase 2Results posted
• A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)CompletedNCT02842827Phase 1/2Results posted
• Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT02834390Phase 1Results posted
• A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT02807558Phase 2Results posted
• Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid LeukemiaCompletedNCT02807272Phase 2Results posted
• HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation CyclophosphamideCompletedNCT02793544Phase 2Results posted
• Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT02785900Phase 3Results posted
• Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell TransplantationActive, not recruitingNCT02782546Phase 2Results posted
• A Study of Pevonedistat in Adult East Asian ParticipantsCompletedNCT02782468Phase 1Results posted
• Home Away From Home - Quality of Life SurveysCompletedNCT02777021Results posted
• An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)CompletedNCT02775903Phase 2Results posted
• Home Away From Home - Medical OutcomesCompletedNCT02774850Results posted
• Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)TerminatedNCT02773732Phase 1/2Results posted
• Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid LeukemiaTerminatedNCT02770820Phase 1/2Results posted
• High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AMLCompletedNCT02768792Phase 2Results posted
• Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid NeoplasmsCompletedNCT02756572Phase 2Results posted
• A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard ChemotherapyCompletedNCT02752035Phase 3Results posted
• Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic MalignanciesCompletedNCT02743351Phase 1/2Results posted
• Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDSCompletedNCT02730299Phase 3Results posted
• Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02728050Phase 1/2Results posted
• UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
• Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 MutationCompletedNCT02719574Phase 1/2Results posted
• An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesTerminatedNCT02712905Phase 1/2Results posted
• A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AMLCompletedNCT02708641Phase 2Results posted
• Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell TransplantCompletedNCT02684162Phase 2Results posted
• A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction ChemotherapyActive, not recruitingNCT02677922Phase 1/2Results posted
• AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02675452Phase 1Results posted
• Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)CompletedNCT02668653Phase 3Results posted
• WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT02666950Phase 2Results posted
• A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid LeukemiaCompletedNCT02665143Phase 2Results posted
• Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid LeukemiaCompletedNCT02658487Phase 2Results posted
• The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS PatientsTerminatedNCT02648932Phase 2Results posted
• Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02642965Phase 1/2Results posted
• Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesCompletedNCT02639559Phase 2Results posted
• Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 MutationTerminatedNCT02634827Phase 2Results posted
• A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)CompletedNCT02632721Phase 1/2Results posted
• Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDSCompletedNCT02626715Phase 2Results posted
• Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AMLCompletedNCT02626338Phase 1/2Results posted
• A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML PatientsTerminatedNCT02614560Phase 1/2Results posted
• An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)CompletedNCT02610777Phase 2Results posted
• Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD ProphylaxisCompletedNCT02593123Phase 2Results posted
• Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)TerminatedNCT02588092Phase 1Results posted
• Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid LeukemiaCompletedNCT02583893Phase 2Results posted
• Reduced Intensity Conditioning Transplant Using Haploidentical DonorsCompletedNCT02581007Phase 2Results posted
• Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02566304Phase 2Results posted
• Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 TrialCompletedNCT02561455Phase 1/2Results posted
• Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AMLCompletedNCT02560025Phase 2Results posted
• High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT02551718Not applicableResults posted
• A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)TerminatedNCT02545283Phase 3Results posted
• A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02538965Phase 2Results posted
• Nivolumab in AML in Remission at High Risk for RelapseCompletedNCT02532231Phase 2Results posted
• Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AMLTerminatedNCT02532010Phase 2Results posted
• Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid LeukemiaCompletedNCT02530476Phase 1/2Results posted
• Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down SyndromeActive, not recruitingNCT02521493Phase 3Results posted
• Alvocidib Biomarker-driven Phase 2 AML StudyTerminatedNCT02520011Phase 2Results posted
• Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related DonorsTerminatedNCT02519712Not applicableResults posted
• 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02509546Phase 1/2Results posted
• A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDSCompletedNCT02488408Phase 1/2Results posted
• Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AMLTerminatedNCT02485353Not applicableResults posted
• CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic SarcomaCompletedNCT02484391Phase 1Results posted
• An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive ChemotherapyCompletedNCT02472145Phase 2/3Results posted
• Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT02464657Phase 1/2Results posted

← Leukemia, Myeloid, Acute overview